摘要葡萄膜黑色素瘤（UM）是成人中最常见的原发性眼内恶性肿瘤。UM在亚洲地区的发病率低于欧美国家，但亚洲UM患者的发病年龄比欧美国家人群更早。随着近年来经济生活水平的提高，UM作为一种罕见的眼内肿瘤，已逐渐被更多人认识。近10年来，我国UM研究呈现出数量多、发展快的特点。其中以非编码RNA为代表的分子遗传学方向、UM潜在抗癌药物的前沿发展和中成药是我国学者的研究热点。在过去的10年中，我国对于UM的发病机制、诊断与治疗方面均有了较完善的认识与研究进展，但与欧美国家相比，在如免疫治疗等前沿研究方面仍有欠缺之处。在我国眼科研究学者、研究团队的进一步努力下，随着我国科研水平的进一步发展，相信能够进一步阐明影响肿瘤的机制，为治疗提供更多可能，从而为改善我国UM患者的预后提供帮助。

abstractsUveal melanoma (UM) is one of the most common primary intraocular malignancy in adults. The incidence of UM is lower in Asia than in Europe and the United States, however, the age of onset of UM patients in Asia is earlier than in the European and American populations. With the improvement of economic living standards in recent years, UM as a rare intraocular tumor has been gradually recognized by the public. In the past 10 years, the research of UM in China has been characterized by a large number and rapid development. Among them, the direction of molecular genetics represented by non-coding RNA, the frontier development of potential anticancer drugs for UM and Chinese traditional medicines are the research hotspots for scholars in China. In the past 10 years, China has made a relatively complete understanding and research progress on the pathogenesis, diagnosis and treatment of UM. On the other hand, compared with European and American countries, China still lacks in frontier research such as immunotherapy. With the further efforts of Chinese ophthalmology researchers and research teams, and with the further development of scientific research in my country, it is believed that the mechanism affecting tumors can be further elucidated, providing more possibilities for treatment and improving the prognosis of UM patients in China.